Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

Cancer

Volumn 116, Issue 22, 2010, Pages 5219-5225

  Choueiri, Toni K ^a,b   Lim, Zita Dubauskas ^c   Hirsch, Michelle S ^b   Tamboli, Pheroze ^c   Jonasch, Eric ^c   McDermott, David F ^d   Cin, Paola Dal ^b   Corn, Paul ^c   Vaishampayan, Ulka ^e   Heng, Daniel Y C ^f   Tannir, Nizar M ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f TOM BAKER CANCER CENTRE   (Canada)

Author keywords

adult translocation renal cell carcinoma (RCC); kidney cancer; sunitinib; targeted therapy; vascular endothelial growth factor (VEGF)

Indexed keywords

ANTINEOPLASTIC AGENT; ARQ 197; BEVACIZUMAB; CANCER VACCINE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME TRANSLOCATION; CHROMOSOME XP; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOGENETICS; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOLID TUMOR; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, X; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PYRROLES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78449267046     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25512     Document Type: Article

References (28)

1. Argani P, Ladanyi M,. Translocation carcinomas of the kidney. Clin Lab Med. 2005; 25: 363-378.
2. Ramphal R, Pappo A, Zielenska M, Grant R, Ngan BY,. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol. 2006; 126: 349-364.
3. Argani P, Ladanyi M,. Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of paediatric renal cell carcinomas. Pathology. 2003; 35: 492-498.
4. Eble J, Sauter G, Epstein JI,. WHO Classification of Tumours. Tumours of the Genitourinary and Male Genital Organs. Lyon: IARC Press; 2004.
5. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007; 31: 1149-1160.
6. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M,. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27: 750-761.
7. Meyer PN, Clark JI, Flanigan RC, Picken MM,. Xp11.2 translocation renal cell carcinoma with very aggressive course in 5 adults. Am J Clin Pathol. 2007; 128: 70-79.
8. Rais-Bahrami S, Drabick JJ, De Marzo AM, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 2007; 70: 178.e3-e6.
9. Armah HB, Parwani AV,. Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: possible Xp11.2 translocation. Pathology. 2008; 40: 306-308.
10. Courtney KD, Choueiri TK,. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep. 2009; 11: 218-226.
11. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008; 26: 127-131.
12. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-763.
13. Choueiri TK, Mosquera JM, Hirsch MS,. A case of adult metastatic xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009; 7: E93-E94.
14. Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A,. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2009 Dec 3. [Epub ahead of print]
15. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296.
16. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
17. Mosquera JM, Dal Cin P, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay in Xp11.2 translocation renal cell carcinomas [abstract]. Mod Pathol. 2008; 21: 172A.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
19. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
20. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008; 32: 656-670.
21. Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009; 15: 1170-1176.
22. Malouf G, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010 Feb 12. [Epub ahead of print]
23. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
24. Lae M, Ahn EH, Mercado GE, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol. 2007; 212: 143-151.
25. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009; 15: 1096-1104.
26. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007; 67: 919-929.
27. Lae M, Saito T, Barr FG,. Expression profiling of pediatric sarcomas with chimeric transcription factors: a study of 153 samples [abstract]. Mod Pathol. 2004; 17 (S1): 330A. Abstract 1390.
28. Phase 2 Study in Patients With MiT Tumors. Available at: Accessed February 1, 2010.